Drug Trial Radar · NCT05867420
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
594
Planned (sponsor's estimate)
Start
Aug 2, 2023
Primary completion
Dec 31, 2026
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- AskGene Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- First posted
- May 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a dose-escalation and dose-expansion study to evaluate the safety, tolerability, and pharmacokinetics of ASKG915 as a single agent or in combination with standard of care (SOC) in patients with selected types of advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
ASKG915Biological
ASKG915 is administered intravenously at a scheduled dose. The drug was given once every 3 weeks or 4 weeks for a cycle.
Paclitaxel + BevacizumabDrug
Paclitaxel is administered intravenously at a dose of 80 mg/m², once weekly on a 21-day cycle. Bevacizumab is administered intravenously at dose of 15mg/kg, once every 3 weeks on a 21-day cycle.
FruquintinibDrug
The recommended dose of Fruquintinib is 5 mg orally once daily, with or without food for the first 21 days of each 28-day cycle.
DocetaxelDrug
Docetaxel is administered intravenously at 75 mg/m², once every 3 weeks on a 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting toxicities (DLTs)Time frame: 21days or 28 days
- Adverse events(AEs)Time frame: From the first dose to 30 days after the last dose
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.